%0 Journal Article
%T Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
%A Thomas R Einarson
%A Maria Geitona
%A Alexandros Chaidemenos
%A Vasiliki Karpouza
%A Theodoros Mougiakos
%A Periklis Paterakis
%A Dimitrios Ploumpidis
%A Dionyssios Potamitis-Komis
%A Roman Zilbershtein
%A Colin Vicente
%A Charles Piwko
%A Panagiotis Kakkavas
%A Konstantina Paparouni
%A Rasmus C D Jensen
%A Michiel E H Hemels
%J Annals of General Psychiatry
%D 2012
%I BioMed Central
%R 10.1186/1744-859x-11-18
%X To compare costs and outcomes of PP-LAI versus RIS-LAI in Greece.A cost-utility analysis was performed using a previously validated decision tree to model clinical pathways and costs over 1£¿year for stable patients started on either medication. Rates were taken from the literature. A local expert panel provided feedback on treatment patterns. All direct costs incurred by the national healthcare system were obtained from the literature and standard price lists; all were inflated to 2011 costs. Patient outcomes analyzed included average days with stable disease, numbers of hospitalizations, emergency room visits, and quality-adjusted life-years (QALYs).The total annual healthcare cost with PP-LAI was ?3529; patients experienced 325£¿days in remission and 0.840 QALY; 28% were hospitalized and 15% received emergency room treatment. With RIS-LAI, the cost was ?3695, patients experienced 318.6£¿days in remission and 0.815 QALY; 33% were hospitalized and 17% received emergency room treatment. Thus, PP-LAI dominated RIS-LAI. Results were generally robust in sensitivity analyses with PP-LAI dominating in 74.6% of simulations. Results were sensitive to the price of PP-LAI.PP-LAI appears to be a cost-effective option for treating chronic schizophrenia in Greece compared with RIS-LAI since it results in savings to the health care system along with better patient outcomes.
%K Paliperidone palmitate
%K Risperidone
%K Long-acting injectables
%K Schizophrenia
%K Pharmacoeconomic analysis
%K Greece
%U http://www.annals-general-psychiatry.com/content/11/1/18/abstract